Dr. Sayed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
410 Market St Suite 400
Chapel Hill, NC 27516Phone+1 984-974-3900Fax+1 984-974-3692- Is this information wrong?
Education & Training
- University of North Carolina HospitalsResidency, Dermatology, 2010 - 2013
- University of North Carolina HospitalsInternship, Internal Medicine, 2009 - 2010
- University of North Carolina at Chapel Hill School of MedicineClass of 2009
Certifications & Licensure
- NC State Medical License 2009 - 2025
- American Board of Dermatology Dermatology
Clinical Trials
- A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. Start of enrollment: 2016 Jun 01
Publications & Presentations
PubMed
- Patient-reported exacerbating factors for hidradenitis suppurativa: A cross sectional study.Rayad B Shams, Christopher J Sayed> ;Journal of the American Academy of Dermatology. 2024 Mar 29
- Global consensus process to establish a core dataset for hidradenitis suppurativa registries.Hannah E Wainman, Nisha S Chandran, John W Frew, Amit Garg, Angela Gibbons, Athena Gierbolini, Barbara Horvath, Gregor B Jemec, Brian Kirby, Joselyn Kirby, Michelle A ...> ;The British Journal of Dermatology. 2024 Mar 15
- Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study.Pearson, L., Westerkam, L., Sayed, C.> ;Clinical Drug Investigation. 2024 Mar 1
- Join now to see all
Books/Book Chapters
Lectures
- Advanced Management Strategies for Hidradenitis SuppurativaAmerican Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
- Development of the North American Clinical Guidelines for Hidradenitis SuppurativaAmerican Academy of Dermatology Annual Meeting, Orlando, FL. - 2/2018
- Office-Based Procedures for Hidradenitis SuppurativaAmerican Academy of Dermatology Annual Meeting, Orlando, FL - 2/2018
Research History
- Co-investigatorA Phase 4, Double-Blind, Randomised,Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa.2018 - Present
- Principal InvestigatorGenome-wide association study of patients with hidradenitis suppurativa.2018 - Present
- Principal Investigator• UCB Biopharma SPRL, HS0001, A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Pharmacokinetics Of Bimekizumab In Subjects With Moderate To Severe Hidradenitis Suppurativa (HS).2018 - Present
- Principal InvestigatorA randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa (SHINE). 2018.2018 - Present
- Co-investigatorA Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® (halobetasol propionate) Cream, 0.05% in the Treatment of Plaque Psoriasis.2017 - Present
- Co-investigatorAn Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult Patients with Hidradenitis Suppurativa.2014 - Present
- Co-investigatorA 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long term safety, tolerability, and efficac2016 - 2018
- Principal InvestigatorFull transcriptome analysis in lesional and non-lesional skin of hidradenitis suppurativa with intention to identify disease signatures and understand molecular mechanism of disease.2016 - 2018
- Co-investigatorSafety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis2017 - 2017
- Principal InvestigatorA randomized, controlled, double blind study to evaluate the efficacy of intralesional triamcinolone in the treatment of hidradenitis suppurativa.2016 - 2017
- Co-investigatorA Phase IIa, Randomized, double-blind, placebo-controlled, multicenter study to assess the safety, tolerability and preliminary efficacy of MEDI8968 in Subjects with Moderate to Severe Hidradenitis Suppurativa (HS).2014 - 2015
Professional Memberships
- Member
- Member
Hospital Affiliations
- University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: